Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.BMC pharmacology & toxicology · 2018
   Trial
2. Status and Quality of Guidelines for Therapeutic Drug Monitoring Based on AGREE II Instrument.Clinical pharmacokinetics · 2023
   Article
3. Is Routine Therapeutic Drug Monitoring of Anti-Retroviral Agents Warranted in Children Living with HIV?The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022
   Article
4. Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine.Journal of mass spectrometry : JMS · 2021
   Review
5. Assessment of lamivudine, zidovudine, lopinavir, and ritonavir plasma levels in HIV-positive pregnant women: Drug monitoring application to improve patient safety.Medicine · 2020
   Article
6. Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study.AIDS research and therapy · 2019
   Article
7. Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.The Journal of antimicrobial chemotherapy · 2019
   Article
8. Prevalence and Associations of Psychological Distress, HIV Infection and HIV Care Service Utilization in East Zimbabwe.AIDS and behavior · 2018
   Article
9. Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.The Annals of pharmacotherapy · 2017
   Review
10. Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.BMC infectious diseases · 2017
    Article
11. Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: a 5-year study.Patient preference and adherence · 2013
    Article
12. Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.The Canadian journal of hospital pharmacy · 2012
    Article
13. Role of the pharmacist caring for people at risk of or living with HIV in Canada.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.